MiRNA expression pattern associated with prognosis in elderly patients with advanced OPSC and OCC

International Journal of Oncology

Volumn 43, Issue 3, 2013, Pages 839-849

  Zhao, Henan ^a   Ding, Yanfang ^a   Tie, Bi ^b   Sun, Zhen Feng ^b   Jiang, Ji Yong ^b   Zhao, Jinyao ^a   Lin, Xingchi ^a   Cui, Shiying ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b Centralab   (China)

Author keywords

Epithelial ovarian cancer; MicroRNA; Ovarian clear cell carcinoma; Ovarian papillary serous carcinoma

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 3; MICRORNA; MICRORNA 30A; MICRORNA 30E; MICRORNA 505; MYC PROTEIN; STATHMIN; STATHMIN1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CLEAR CELL CARCINOMA; FEMALE; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; OUTCOME ASSESSMENT; OVARIAN CLEAR CELL CARCINOMA; OVARIAN PAPILLARY SEROUS CARCINOMA; OVARY CARCINOMA; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROTEIN TARGETING; SURVIVAL RATE;

ADULT; AGE FACTORS; AGED; CYSTADENOCARCINOMA, SEROUS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICROARRAY ANALYSIS; MICRORNAS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84880605092     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1988     Document Type: Article

References (29)

1. Pignata S and Vermorken JB: Ovarian cancer in the elderly. Crit Rev Oncol Hematol 49: 77-86, 2004.
2. Boren T, Xiong Y, Hakam A, et al: MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol 113: 249-255, 2009.
3. Liu JF, Hirsch MS, Lee H and Matulonis UA: Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinoma. Gynecol Oncol 115: 401-406, 2009.
4. Moore DH, Kauderer JT, Bell J, Curtin JP and Van Le L: An assessment of age and other factors influencing protocol versus alternative treatments for patients with epithelial ovarian cancer referred to member institutions: a Gynecologic Oncology Group study. Gynecol Oncol 94: 368-374, 2004.
5. Shih KK, Qin LX, Tanner EJ, et al: A microRNA survival signature (MiSS) for advanced ovarian cancer. Gynecol Oncol 121: 444-450, 2011.
6. Yancik R, Ries LG and Yates JW: Ovarian cancer in the elderly: an analysis of Surveillance, Epidemiology, and End Results Program data. Am J Obstet Gynecol 154: 639-647, 1986.
7. Chan JK, Teoh D, Hu JM, Shin JY, Osann K and Kapp DS: Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol 109: 370-376, 2008.
8. Wyman SK, Parkin RK, Mitchell PS, et al: Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. PLoS One 4: e5311, 2009.
9. Van Jaarsveld MT, Helleman J, Berns EM and Wiemer EA: MicroRNAs in ovarian cancer biology and therapy resistance. Int J Biochem Cell Biol 42: 1282-1290, 2010.
10. Sugiyama T, Kamura T, Kigawa J, et al: Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 88: 2584-2589, 2000.
11. Yoshida S, Furukawa N, Haruta S, et al: Theoretical model of treatment strategies for clear cell carcinoma of the ovary: focus on perspectives. Cancer Treat Rev 35: 608-615, 2009.
12. Pectasides D, Pectasides E, Psyrri A and Economopoulos T: Treatment issues in clear cell carcinoma of the ovary: a different entity? Oncologist 11: 1089-1094, 2006.
13. Snowdon J, Zhang X, Childs T, Tron VA and Feilotter H: The microRNA-200 family is upregulated in endometrial carcinoma. PLoS One 6: e22828, 2011.
14. Cui S, Li C, Ema M, Weinstein J and Quaggin SE: Rapid isolation of glomeruli coupled with gene expression profiling identifies downstream targets in Pod1 knockout mice. J Am Soc Nephrol 16: 3247-3255, 2005.
15. American Cancer Society: Global Cancer Facts and Figures 2007. American Cancer Society Inc, Atlanta, GA, 2007.
16. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds): SEER Cancer Statistics Review: 1975-2008. National Institutes of Health, Bethesda, MD, 2011.
17. Kim MS, In SG, Park OJ, et al: Increased expression of activating transcription factor 3 is related to the biologic behavior of cutaneous squamous cell carcinomas. Hum Pathol 42: 954-959, 2011.
18. Li ZD, Hu XW, Wang YT and Fang J: Apigenin inhibits proliferation of ovarian cancer A2780 cells through Id1. FEBS Lett 583: 1999-2003, 2009.
19. Hai T and Hartman MG: The molecular biology and nomenclature of the activating transcription factor/cAMP responsive element binding family of transcription factors: activating transcription factor proteins and homeostasis. Gene 273: 1-11, 2001.
20. Thompson MR, Xu D and Williams BR: ATF3 transcription factor and its emerging roles in immunity and cancer. J Mol Med (Berl) 87: 1053-1060, 2009.
21. Pelzer AE, Bektic J, Haag P, et al: The expression of transcription factor activating transcription factor 3 in the human prostate and its regulation by androgen in prostate cancer. J Urol 175: 1517-1522, 2006.
22. Janz M, Hummel M, Truss M, et al: Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3), which promotes viability of Hodgkin/Reed-Sternberg cells. Blood 107: 2536-2539, 2006.
23. Bandyopadhyay S, Wang Y, Zhan R, et al: The tumor metastasis suppressor gene Drg-1 down-regulates the expression of activating transcription factor 3 in prostate cancer. Cancer Res 66: 11983-11990, 2006.
24. Ishiguro T, Nagawa H, Naito M and Tsuruo T: Inhibitory effect of ATF3 antisense oligonucleotide on ectopic growth of HT29 human colon cancer cells. Jpn J Cancer Res 91: 833-836, 2000.
25. Hsieh SY, Huang SF, Yu MC, et al: Stathmin1 overexpression associated with polyploidy, tumor-cell invasion, early recurrence, and poor prognosis in human hepatoma. Mol Carcinog 49: 476-487, 2010.
26. Lee HS, Lee DC, Park MH, et al: STMN2 is a novel target of beta-catenin/TCF-mediated transcription in human hepatoma cells. Biochem Biophys Res Commun 345: 1059-1067, 2006.
27. Su D, Smith SM, Preti M, et al: Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel. Cancer 115: 2453-2463, 2009.
28. Ponzielli R, Katz S, Barsyte-Lovejoy D and Penn LZ: Cancer therapeutics: targeting the dark side of Myc. Eur J Cancer 41: 2485-2501, 2005.
29. Lee YY, Kim TJ, Kim MJ, et al: Prognosis of ovarian clear cell carcinoma compared to other histological subtypes: a meta-analysis. Gynecol Oncol 122: 541-547, 2011.